FDA's Final PRO Guidance Grounds Policy With More Details
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
FDA's final guidance on patient-reported outcomes measurements adds more detail and information on practical application to the draft guidance issued several years ago - in keeping with the comments made on the draft
You may also be interested in...
Comparative Effectiveness Reaches Into Drug Reviews, FDA Documents Show
As the health care reform debate focuses on the appropriate role of comparative effectiveness research, a look at FDA’s review practices gives some insight into how the agency already takes the concept into account in its review decisions.
Comparative Effectiveness Reaches Into Drug Reviews, FDA Documents Show
As the health care reform debate focuses on the appropriate role of comparative effectiveness research, a look at FDA’s review practices gives some insight into how the agency already takes the concept into account in its review decisions.
It's Up To Stakeholders To Further The PRO Measurement Field, FDA Said
FDA is preparing to issue its final guidance on patient-reported outcomes soon - which will codify the agency's approach to validating PROs used as clinical endpoints - but a recent workshop made clear that there is still a substantial amount of work to be done on identifying and creating appropriate measurements of patient-, clinician- and caregiver-reported outcomes